Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Receives Notification of Nasdaq Non-Compliance

NEW YORK (GenomeWeb) – Rosetta Genomics said today that it has received notification from the Nasdaq that it no longer meets the exchange's stockholder equity listing requirement.

According to Rosetta, it has received a letter from the Nasdaq indicating that it is not in compliance with a listing rule requiring a minimum of $2.5 million in stockholders' equity. The company said it has 45 days from Oct. 24 to submit a specific plan to regain compliance with this requirement. If the plan is accepted, the Nasdaq may provide Rosetta with up to 180 calendar days from the date of the notification to regain compliance.

Earlier this year, Rosetta effected a 1-for-12 reverse stock split after failing to meet the Nasdaq's $1 minimum bid price requirement.

During early morning trading, shares of Rosetta were up $.01 at $.80.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.